Interferon subtype gene therapy for regulating cytomegalovirus disease

Area of Science:

• Immunology
• Gene Therapy
• Virology

Background:

• Type I interferons (IFNs) are crucial for immune responses.
• DNA vaccination is a promising method for delivering therapeutic genes.
• Cytomegalovirus (CMV) infection poses significant health challenges.

Purpose of the Study:

• To investigate the immunomodulatory effects of type I IFN gene delivery via DNA vaccination.
• To explore parameters influencing the efficacy of IFN gene therapy.
• To evaluate the adjuvant potential of type I IFN genes in viral vaccination.

Main Methods:

• Intramuscular inoculation of mice with recombinant mammalian expression vectors encoding type I IFN subtypes.
• Optimization of DNA vaccination parameters including DNA concentration, subtype selection, and timing.
• Assessment of immune response stimulation and transgene expression.
• Evaluation of therapeutic efficacy in a mouse model of CMV infection and disease.
• Testing adjuvant effects in combination with CMV glycoprotein B DNA vaccination.

Main Results:

• Type I IFN gene delivery via DNA vaccination effectively stimulated immune responses, promoting a Th1-like response.
• Parameters such as IFN subtype, DNA concentration, and immunization timing influenced therapeutic efficacy.
• Pretreatment with bupivacaine enhanced transgene expression.
• Type I IFN gene therapy demonstrated potent adjuvant properties, enhancing viral-specific immunity and reducing myocarditis severity when used with CMV vaccination.

Conclusions:

• Type I IFN gene therapy delivered as naked DNA is a potent immunomodulator.
• This approach can regulate viral infections and disease, offering therapeutic benefits.
• IFN gene therapy shows significant potential as an adjuvant for viral vaccines.